Paul Jeng
Stock Analyst at Guggenheim
(0.50)
# 4,332
Out of 5,020 analysts
33
Total ratings
37.9%
Success rate
-9.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Paul Jeng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBTX Nanobiotix | Reiterated: Buy | $64 | $27.90 | +129.39% | 2 | Sep 25, 2026 | |
| ADAG Adagene | Reiterated: Buy | $10 | $2.93 | +241.30% | 7 | Sep 10, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $54 → $57 | $37.81 | +50.75% | 9 | Sep 9, 2026 | |
| CHRS Coherus Oncology | Reiterated: Buy | $12 → $10 | $1.16 | +762.07% | 2 | Aug 6, 2026 | |
| CRBP Corbus Pharmaceuticals Holdings | Reiterated: Buy | $45 | $6.34 | +609.78% | 2 | Jun 2, 2026 | |
| IMTX Immatics | Reiterated: Buy | $19 | $8.44 | +125.12% | 5 | May 12, 2026 | |
| CNTX Context Therapeutics | Reiterated: Buy | $5 | $0.3144 | +1,490.33% | 4 | May 6, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Hold | n/a | $30.61 | n/a | 1 | Sep 17, 2025 | |
| TARA Protara Therapeutics | Initiated Coverage: Buy | $50 | $2.76 | n/a | 1 | Jul 29, 2020 |
Nanobiotix
Sep 25, 2026
Reiterated: Buy
Price Target: $64
Current: $27.90
Upside: +129.39%
Adagene
Sep 10, 2026
Reiterated: Buy
Price Target: $10
Current: $2.93
Upside: +241.30%
IDEAYA Biosciences
Sep 9, 2026
Reiterated: Buy
Price Target: $54 → $57
Current: $37.81
Upside: +50.75%
Coherus Oncology
Aug 6, 2026
Reiterated: Buy
Price Target: $12 → $10
Current: $1.16
Upside: +762.07%
Corbus Pharmaceuticals Holdings
Jun 2, 2026
Reiterated: Buy
Price Target: $45
Current: $6.34
Upside: +609.78%
Immatics
May 12, 2026
Reiterated: Buy
Price Target: $19
Current: $8.44
Upside: +125.12%
Context Therapeutics
May 6, 2026
Reiterated: Buy
Price Target: $5
Current: $0.3144
Upside: +1,490.33%
Immunocore Holdings
Sep 17, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $30.61
Upside: n/a
Protara Therapeutics
Jul 29, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $2.76
Upside: n/a